Real-world efficacy of dupilumab in four cases of paediatric-onset fibrostenotic eosinophilic esophagitis.
Clin Exp Pharmacol Physiol
; 51(8): e13903, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38889994
ABSTRACT
Eosinophilic esophagitis (EoE) is an increasingly prevalent immune-mediated disease that leads to chronic changes in the oesophagus. These changes can include strictures, narrowing, and stenosis, mediated by an interleukin (IL)-13 pathway, which leads to remodelling and fibrosis through increasing migration of fibroblasts and subepithelial fibrosis via collagen deposition 1. IL-13 downregulates TSPAN12, a gene whose expression regulates fibrosis and causes changes in barrier function and higher rates of fibrostenosis in EoE. Dupilumab, a biologic therapy aimed at blocking IL-13, has been shown to improve EoE-related inflammation and fibrosis in clinical trials. We report here four unique patients with documented oesophageal stenosis with inability to pass a paediatric endoscope due to structuring disease, requiring dilation, who had resolution of their oesophageal narrowing following dupilumab therapy.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Esofagitis Eosinofílica
/
Anticuerpos Monoclonales Humanizados
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Clin Exp Pharmacol Physiol
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos